Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE
jRCT2063240083Recruiting
- Sponsor
- Pharmbio Korea Inc.
- Start
- Feb 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of PAL-222 in exudative macular degeneration, sponsored by Pharmbio Korea Inc. Primary endpoints: Adverse events, Clinical testing data changes and 3 more. Started Feb 2025; status: recruiting.
02
Drugs
PAL-222
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on jRCT2063240083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2063240083.